May. 14 at 8:07 PM
$ETON « Back to news
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
Q1 2026 product sales of
$24.3 million, representing 73% growth over Q1 2025
Raising full year revenue guidance - now expect 2026 revenue to exceed
$120 million, up from previous guidance of
$110 million
Q1 2026 fully diluted GAAP EPS of
$0.05, non-GAAP fully diluted EPS of
$0.14, and Adjusted EBITDA of
$5.7 million
Received FDA approval for and launched DESMODA™
Acquired and relaunched HEMANGEOL®
Announced initiation of ET-700 clinical study, the Company’s extended-release formulation of zinc acetate
Received FDA clearance to proceed on INCRELEX® label harmonization study
